Szymon Buda

Dr. Szymon Buda

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2012 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
MWMarta Woyciechowska
Marta Woyciechowska
GFGwenael Forcher
Gwenael Forcher
SBSzymon Buda
Szymon Buda
JMJacek Mlynarski
Jacek Mlynarski
An unexpected yet disciplined course of catalytic Mukaiyama-aldol reaction instead of the expected vinylogous Mukaiyama-aldol reaction has been observed for the reaction of silyloxyfuran with various aldehydes under Lewis acid catalytic control in water-containing solvents.

26 July 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
LKLucja Kudla
Lucja Kudla
RBRyszard Bugno
Ryszard Bugno
USUrszula Skupio
Urszula Skupio
LWLucja Wiktorowska
Lucja Wiktorowska
WSWojciech Solecki
Wojciech Solecki
RPRyszard Przewlocki
Ryszard Przewlocki
Background and Purpose: The concept of opioid ligands biased towards the G protein pathway with minimal recruitment of β‐arrestin‐2 is a promising approach for the development of novel, efficient, and potentially nonaddictive opioid therapeutics. A recently discovered biased μ‐opioid receptor agonist, PZM21, showed analgesic effects with reduced side effects. Here, we aimed to further investigate the behavioural and biochemical properties of PZM21.Experiment Approach: We evaluated antinociceptive effects of systemic and intrathecal PZM21 administration. Its addiction‐like properties were determined using several behavioural approaches: conditioned place preference, locomotor sensitization, precipitated withdrawal, and self‐administration. Also, effects of PZM21 on morphine‐induced antinociception, tolerance, and reward were assessed. Effects of PZM21 on striatal release of monoamines were evaluated using brain microdialysis.Key Results: PZM21 caused long‐lasting dose‐dependent antinociception. It did not induce reward‐ and reinforcement‐related behaviour; however, its repeated administration led to antinociceptive tolerance and naloxone‐precipitated withdrawal symptoms. Pretreatment with PZM21 enhanced morphine‐induced antinociception and attenuated the expression of morphine reward. In comparison to morphine, PZM21 administration induced a moderate release of dopamine and a robust release of 5‐HT in the striatum.Conclusions and Implications: PZM21 exhibited antinociceptive efficacy, without rewarding or reinforcing properties. However, its clinical application may be restricted, as it induces tolerance and withdrawal symptoms. Notably, its ability to diminish morphine reward implies that PZM21 may be useful in treatment of opioid use disorders.


13 May 2013 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
SBSzymon Buda
Szymon Buda
PGPatrycja Gołębiowska
Patrycja Gołębiowska
JMJacek Mlynarski
Jacek Mlynarski

21 March 2019 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
KGKatarzyna Grychowska
Katarzyna Grychowska
SCSéverine Chaumont-Dubel
Séverine Chaumont-Dubel
RKRafał Kurczab
Rafał Kurczab
PKPaulina Koczurkiewicz
Paulina Koczurkiewicz
CDCaroline Deville
Caroline Deville
PZPaweł Zajdel
Paweł Zajdel

23 June 2015 in Crystal Growth & Design
Verified
Journal Article
Closed access
SCSzymon Chorazy
Szymon Chorazy
MRMateusz Reczyński
Mateusz Reczyński
Robert PodgajnyRobert Podgajny
Robert Podgajny
WNWojciech Nogaś
Wojciech Nogaś
SBSzymon Buda
Szymon Buda
BSBarbara Sieklucka
Barbara Sieklucka